2025-522056-10-01招募中3 期
A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients with von Willebrand Disease (VIVID-6)
Vega Therapeutics Inc.1 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2025年12月8日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Annualized bleeding rate (ABR)
研究概览
简要总结
To assess the efficacy of subcutaneous (SC) VGA039 prophylaxis on bleeding events in subjects with von Willebrand Disease (VWD) who previously did not receive von Willebrand Factor (VWF)-containing concentrates on a prophylactic basis
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects, 18-75 years of age, inclusive
- •No clinically significant abnormalities in 12-lead ECG determined at screening.
- •No clinically significant abnormalities in vital signs (blood pressure, pulse rate, respiration rate, oral temperature) determined at screening.
- •Documented diagnosis of and laboratory results consistent with VWD of any type.
- •Subjects must have a historical ABR (excluding menstrual bleeds and bleeds under the skin) ≥ 12 over the 6 months prior to screening.
- •Subjects must be judged by the investigator to be suitable candidates for routine prophylaxis to reduce the frequency of bleeding episodes.
- •Subjects must have a hemoglobin level ≥ 8 g/dL and platelet count ≥ 100 × 10^9/L (or ≥ 50 × 10^9/L if diagnosed with Type 2B VWD) at screening.
排除标准
- •Use of routine prophylaxis of VWF-containing concentrates defined as at least 1 VWF-containing concentrate infusion to prevent or reduce bleeding per week during the previous 6 months prior to screening.
- •Planning to initiate routine prophylaxis with VWF-containing concentrates or any other hemostatic treatment during the study.
- •Detection of FV Leiden or Prothrombin G20210A mutation, or laboratory results consistent with protein C or S deficiency, antithrombin deficiency, or antiphospholipid antibody syndrome at screening
- •Subjects with other known pro-thrombotic disorders or abnormal findings in any prior laboratory thrombophilia evaluation
- •Previous or current treatment for or history of coronary artery diseases, atrial fibrillation, mechanical heart valves or other intravascular foreign materials, venous or arterial thrombosis (Common Terminology Criteria for Adverse Events [CTCAE] Grade >1), or ischemic disease (except for catheter associated thrombosis). Subjects with a positive family history of venous or arterial thromboembolism should also be excluded
- •Severe liver disease (alanine aminotransferase [ALT] and aspartate transaminase [AST] levels >5 times of ULN) or severe kidney disease (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2)
- •FVIII activity > lower limit of normal (LLN) during Screening. The LLN shall be determined using the assay-specific reference ranges.
- •Subjects who are pregnant or breastfeeding
结局指标
主要结局
Annualized bleeding rate (ABR)
Annualized bleeding rate (ABR)
次要结局
未报告次要终点
研究者
Clinical Trials
Scientific
Vega Therapeutics Inc.
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).NCT07265232Lantu Biopharma15
进行中（未招募）
3 期
A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency2024-513962-20-00Grifols Therapeutics LLC120
未知
3 期
DU-176b Phase 3 Clinical Study (Venous Thromboembolism) -Randomized Double-Blind Study of DU-176b in Patients Undergoing Total Knee Arthroplasty with Enoxaparin as an Active Control -jRCT2080220701DAIICHISANKYO Co.,Ltd.520
未知
3 期
DU-176b Phase 3 Clinical Study (Venous Thromboembolism) -Randomized Double-Blind Study of DU-176b in Patients Undergoing Total Knee Arthroplasty with Enoxaparin as an Active ControlJPRN-jRCT2080220701DAIICHISANKYO Co.,Ltd.520
未知
3 期
DU-176b Phase III Clinical Study (Venous Thromboembolism) Randomized Double-Blind Study of DU-176b in Patients Undergoing Total Hip Arthroplasty with Enoxaparin as an Active ControlJPRN-jRCT2080220743DAIICHISANKYO Co.,Ltd.600